Observational studyCancer science2026

Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.

Kinnosuke Matsumoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.